Industry News
Pharmaceutical Industry News
With phase 3 results that have…
With phase 3 results that have “exceeded” BioMarin’s expectations, the California biotech looks set up to gain a label expansion for its top-selling product, dwarfism drug Voxzogo.
Healthcare agencies remain at the…
Healthcare agencies remain at the forefront of pharmaceutical marketing, but new technologies and shifting political dynamics are putting increasing pressure on the industry.
The French Civil Servant Accused of Drugging More Than 100 Women
For years, prosecutors have accused Christian Nègre, once a senior official, of slipping diuretics into women’s drinks. Despite admitting to some accusations in an interview with a French daily, he is yet to stand trial.
JR Raelin of SynOx Therapeutics…
JR Raelin of SynOx Therapeutics and Krishna GS of ZS discuss how emerging pharma teams can design scalable, compliant tech roadmaps as agentic AI expectations rise.
An Ipsen-commissioned survey has…
An Ipsen-commissioned survey has identified widespread problems with the transition from pediatric to adult healthcare, prompting the drugmaker to call for more resources to help people manage the shift.
The differentiator isn’t…
The differentiator isn't algorithms; it's data quality. Discover the two critical bottlenecks in oncology RWE and how to build AI systems you can act on with confidence.
Biopharma sales trended upward in…
Biopharma sales trended upward in the first quarter of this year as eight of the industry’s top-25 companies achieved double-digit year-over-year growth. It was an uptick from 2025 when there were six drugmakers that had
BMS is the latest large pharma…
BMS is the latest large pharma company to make a major bet on AI, announcing a sweeping agreement with Anthropic to deploy its AI tool Claude as the “shared intelligence platform” across the drugmaker’s global
Gilead has broadened its…
Gilead has broadened its partnership with Korean manufacturer Yuhan, agreeing to a $140 million supply deal for active pharmaceutical ingredients for an undisclosed product.
After some six years at the post,…
After some six years at the post, Amgen’s finance chief is telegraphing his exit from the California pharma by early next year.
CG Life has hired Collette…
CG Life has hired Collette “Coco” Douaihy, bringing the former Dentsu International, Evoke and Digitas Health leader on board to head up its creative offering to biopharma companies.
Tarsus Pharmaceuticals has spent…
Tarsus Pharmaceuticals has spent the past three years marketing its way out of a largely unknown but stigmatized condition: Demodex blepharitis, an eyelid disease caused by mites.
How targeted protein degraders…
How targeted protein degraders could eliminate KRAS and redefine cancer care – insights from Astellas’ Head of Oncology Development
How Has Your Shopping Changed in the Era of Weight-Loss Drugs?
In the last few years, weight-loss drugs like Ozempic have altered how many Americans think about clothes and getting dressed.
Two months after UCB revealed the…
Two months after UCB revealed the success of Bimzelx in a head-to-head trial against AbbVie’s Skyrizi in patients with psoriatic arthritis, the Belgian drugmaker has unveiled the results. In the phase 3b study, 49% of
Roche has signed a voluntary…
Roche has signed a voluntary license agreement providing its popular influenza antiviral drug Xofluza for generic drugmakers to copy in 129 developing countries.
With questions already swirling…
With questions already swirling about the actual affordability impact of the government’s drug purchasing portal TrumpRx, the White House is updating the platform to address a key gap in the medicines it lists, albeit with
Takeda plans to appeal after a…
Takeda plans to appeal after a federal jury found it liable in a landmark pay-for-delay antitrust case and ordered the Japanese drugmaker to pay $885 million in damages, a figure that could be roughly tripled
TrumpRx Adds Generic Drugs, With Mark Cuban, GoodRx and Amazon
President Trump announced the addition of 600 medicines to his online drugstore as he appeals to Americans concerned about high drug prices and affordability.
A Novartis cross-border…
A Novartis cross-border partnership is turning into a standoff. The Swiss pharma has unilaterally terminated a plant leasing contract with Chinese CDMO Porton Pharma Solutions after a regulatory hiccup.